A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors

PURPOSE: To define maximum tolerated dose (MTD), clinical toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered in combination with docetaxel once every 21 days in patients with advanced solid tumor malignancies. EXPERIMENTAL DESIGN: Docetaxel was admi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Iyer, Gopa, Morris, Michael J., Rathkopf, Dana, Slovin, Susan F., Steers, Macaulay, Larson, Steven M., Schwartz, Lawrence H., Curley, Tracy, DeLaCruz, Anthony, Ye, Qing, Heller, Glenn, Egorin, Merrill J., Ivy, S. Percy, Rosen, Neal, Scher, Howard I., Solit, David B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3471133/
https://ncbi.nlm.nih.gov/pubmed/22124669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-011-1789-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak